Follow the BriaCell Therapeutics Corp. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €29.5m. The latest transaction was reported on 7 July 2026 (46 - Compensation for services). Among the most active insiders: Bondarenko, Jamieson. All data is accessible without an account.
14
Insider Decl.
n/a
Thresholds
€2m
3 ops.
Buy Volume
n/a
n/a
Sell Volume
23Σ signal
Buys €2mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
22,000 shares@ US$5.3547.9% of flowCommon SharesSEC:0001493152-22-036060:0
Canonical exit: 20 Mar 2023 (T+90)
14 of 14 declarations
Acerca de BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos inmunoterapéuticos para el cáncer. Se especializa en terapias basadas en células dendríticas para atacar tumores.